These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 30238350)
1. KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma. Ciesielski MJ; Bu Y; Munich SA; Teegarden P; Smolinski MP; Clements JL; Lau JYN; Hangauer DG; Fenstermaker RA J Neurooncol; 2018 Dec; 140(3):519-527. PubMed ID: 30238350 [TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361). Smolinski MP; Bu Y; Clements J; Gelman IH; Hegab T; Cutler DL; Fang JWS; Fetterly G; Kwan R; Barnett A; Lau JYN; Hangauer DG J Med Chem; 2018 Jun; 61(11):4704-4719. PubMed ID: 29617135 [TBL] [Abstract][Full Text] [Related]
3. ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme. Cherry AE; Haas BR; Naydenov AV; Fung S; Xu C; Swinney K; Wagenbach M; Freeling J; Canton DA; Coy J; Horne EA; Rickman B; Vicente JJ; Scott JD; Ho RJ; Liggitt D; Wordeman L; Stella N Mol Cancer Ther; 2016 Sep; 15(9):2018-29. PubMed ID: 27325686 [TBL] [Abstract][Full Text] [Related]
4. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. Naing A; Cohen R; Dy GK; Hong DS; Dyster L; Hangauer DG; Kwan R; Fetterly G; Kurzrock R; Adjei AA Invest New Drugs; 2013 Aug; 31(4):967-73. PubMed ID: 23361621 [TBL] [Abstract][Full Text] [Related]
5. 6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability. Du S; Sarver JG; Trabbic CJ; Erhardt PW; Schroering A; Maltese WA Cancer Chemother Pharmacol; 2019 Feb; 83(2):237-254. PubMed ID: 30426158 [TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Antonarakis ES; Heath EI; Posadas EM; Yu EY; Harrison MR; Bruce JY; Cho SY; Wilding GE; Fetterly GJ; Hangauer DG; Kwan MF; Dyster LM; Carducci MA Cancer Chemother Pharmacol; 2013 Apr; 71(4):883-92. PubMed ID: 23314737 [TBL] [Abstract][Full Text] [Related]
7. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival. Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats T Eur J Pharmacol; 2009 Jan; 602(2-3):188-93. PubMed ID: 19027730 [TBL] [Abstract][Full Text] [Related]
8. A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models. Boumendjel A; McLeer-Florin A; Champelovier P; Allegro D; Muhammad D; Souard F; Derouazi M; Peyrot V; Toussaint B; Boutonnat J BMC Cancer; 2009 Jul; 9():242. PubMed ID: 19619277 [TBL] [Abstract][Full Text] [Related]
9. Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma. Yung R; Seyfoddin V; Guise C; Tijono S; McGregor A; Connor B; Ching LM Cancer Chemother Pharmacol; 2014 Mar; 73(3):639-49. PubMed ID: 24477604 [TBL] [Abstract][Full Text] [Related]
10. Targeting SRC and tubulin in mucinous ovarian carcinoma. Liu T; Hu W; Dalton HJ; Choi HJ; Huang J; Kang Y; Pradeep S; Miyake T; Song JH; Wen Y; Lu C; Pecot CV; Bottsford-Miller J; Zand B; Jennings NB; Ivan C; Gallick GE; Baggerly KA; Hangauer DG; Coleman RL; Frumovitz M; Sood AK Clin Cancer Res; 2013 Dec; 19(23):6532-43. PubMed ID: 24100628 [TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure. Wang L; Zheng Y; Li D; Yang J; Lei L; Yan W; Zheng W; Tang M; Shi M; Zhang R; Cai X; Ni H; Ma X; Li N; Hong F; Ye H; Chen L J Med Chem; 2021 Jun; 64(12):8127-8141. PubMed ID: 34081857 [TBL] [Abstract][Full Text] [Related]
12. Targeting βIII-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics. Katsetos CD; Draber P; Kavallaris M Anticancer Agents Med Chem; 2011 Oct; 11(8):719-28. PubMed ID: 21707498 [TBL] [Abstract][Full Text] [Related]
13. Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors. De Witt M; Gamble A; Hanson D; Markowitz D; Powell C; Al Dimassi S; Atlas M; Boockvar J; Ruggieri R; Symons M Mol Med; 2017 Apr; 23():50-56. PubMed ID: 28386621 [TBL] [Abstract][Full Text] [Related]
14. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft. Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830 [TBL] [Abstract][Full Text] [Related]